Relationship between CD4 cell count and serious long-term complications among HIV-positive individuals
Authors:
- 1 January 2014
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 9 (1) , 63-71
Abstract
Purpose of reviewTo summarize recent findings on the relationship between CD4 cell count metrics and selected serious clinical outcomes, and to deduce implications for CD4 cell count monitoring in treated HIV infection and the timing of combination antiretroviral therapy initiation.Recent findingsIn treated HIV infection, a higher latest CD4 cell count is associated with a lower short-term risk of serious non-AIDS events (often composite endpoints) even in CD4 cell count strata more than 350/l. Knowledge of alternate CD4 cell count metrics, such as CD4 cell count slope, nadir level and time spent under specific CD4 cell count thresholds, does not seem to confer additional prognostic information beyond that achieved by current CD4 cell count. Latest CD4 cell count is strongly associated with a short-term risk of infection-related non-AIDS malignancies, and serious hepatic events; however, the evidence is inconsistent for cardiovascular outcomes. Studies vary significantly in definitions of composite endpoints as well as the rigorousness of outcome ascertainment, which could explain the heterogeneity in results.SummaryCurrent CD4 cell count, but not other metrics, could be an important clinical tool to predict the short-term risk of serious non-AIDS events in treated HIV-positive individuals. An earlier initiation of therapy at CD4 cell count more than 350/l or above 500/l is likely to improve long-term CD4 cell count metrics. Whether it provides net individual clinical benefit requires a randomized trial.Keywords
This publication has 52 references indexed in Scilit:
- HIV Infection and the Risk of Acute Myocardial InfarctionJAMA Internal Medicine, 2013
- Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort StudyHIV Medicine, 2012
- AIDS and Non-AIDS Morbidity and Mortality Across the Spectrum of CD4 Cell Counts in HIV-Infected Adults Before Starting Antiretroviral Therapy in Côte d’IvoireClinical Infectious Diseases, 2011
- All-cause mortality in treated HIV-infected adults with CD4 >=500/mm3 compared with the general population: evidence from a large European observational cohort collaborationInternational Journal of Epidemiology, 2011
- Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort StudyClinical Infectious Diseases, 2011
- Risk of cerebrovascular events in persons with and without HIVAIDS, 2011
- Untreated HIV: harmful even at high CD4 cell countsThe Lancet, 2010
- Antiretroviral therapy and management of HIV infectionThe Lancet, 2010
- Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μL in Europe and North America: a pooled cohort observational studyThe Lancet, 2010
- Inferior Clinical Outcome of the CD4+ Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV RNA Levels during Follow-upThe Journal of Infectious Diseases, 2008